ArticleBiomaterials2019
A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8
Article in Biomaterials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 88 citations in OpenAlex.
- Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial.Nature communications · 2023Trial
- Engineering microspheres for breast cancer: integrating tumor modeling, diagnostics, and targeted treatment.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Personalized Cancer Immunotherapy Boosted by cGAS-STING-Targeted Nanovaccines in Combination With Nutrient Modulation.Exploration (Beijing, China) · 2025Article
- cGAS-STING signaling in melanoma: regulation and therapeutic targeting.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Article
- Profile of STING agonist and inhibitor research: a bibliometric analysis.Frontiers in pharmacology · 2025Article
- An Immunogenic Cell Death-Related Gene Signature Predicts the Prognosis and Immune Infiltration of Cervical Cancer.Cancer informatics · 2025Article
- Novel Modifications and Delivery Modes of Cyclic Dinucleotides for STING Activation in Cancer Treatment.International journal of nanomedicine · 2025Review
- cGAS/STING in skin melanoma: from molecular mechanisms to therapeutics.Cell communication and signaling : CCS · 2024Review
- Recent advancements in cGAS-STING activation, tumor immune evasion, and therapeutic implications.Medical oncology (Northwood, London, England) · 2024Review
- Review
- Polymeric cGAMP microparticles affect the immunogenicity of a broadly active influenza mRNA lipid nanoparticle vaccine.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Bis-2'-F-cGMolecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Review
- Comparative study of acetalated-dextran microparticle fabrication methods for a clinically translatable subunit-based influenza vaccine.International journal of pharmaceutics · 2024Article
- Biomaterials' enhancement of immunotherapy for breast cancer by targeting functional cells in the tumor micro-environment.Frontiers in immunology · 2024Review
- Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives.Materials today. Bio · 2023Review
- Humoral Response to the Acetalated Dextran M2e Vaccine is Enhanced by Antigen Surface Conjugation.Bioconjugate chemistry · 2023Article
- Article
- Vinyl Sulfone-functionalized Acetalated Dextran Microparticles as a Subunit Broadly Acting Influenza Vaccine.The AAPS journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Immunotherapies have significantly improved cancer patient survival, but response rates are still limited. Thus, novel formulations are needed to expand the breadth of immunotherapies. Pathogen associated molecular patterns (PAMPs) can be used to stimulate an immune response, but several pathogen recognition receptors are located within the cell, making delivery challenging. We have employed the biodegradable polymer acetalated dextran (Ace-DEX) to formulate PAMP microparticles (MPs) in order to enhance intracellular delivery. While treatment with four different PAMP MPs resulted in tumor growth inhibition, cyclic GMP-AMP (cGAMP) MPs were most effective. cGAMP MPs showed anti-tumor efficacy at doses 100-1000 fold lower than published doses of soluble cGAMP in two murine tumor models. Treatment with cGAMP MPs resulted in increased natural killer cell numbers in the tumor environment. Immune cell depletion studies confirmed that NK cells were responsible for the anti-tumor efficacy in an aggressive mouse melanoma model. NK cells and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.